معرفی
Lukas Edward Dow is a Professor of Biochemistry and Biophysics at Weill Cornell Medical College (2025-present) and holds a secondary appointment in Medicine. His research spans genetic and non-genetic resistance mechanisms in KRAS-driven cancers, WNT signaling, and CRISPR-based cancer modeling.
- Ph.D. and B.Sc. from University of Melbourne
- Focus on CRC, pancreatic, breast, and prostate cancers
Research interests include genetic resistance mechanisms, CRISPR applications, WNT pathway dependencies, and tumor microenvironment dynamics. Key publications reveal trends in mutant-specific therapies, epithelial plasticity, and precision genome editing.
Current research projects funded by National Cancer Institute and Department of Defense investigate KRAS allelic imbalance, R-Spondin sensitization, and WNT pathway alterations. External collaborations include scientific advisory roles at Mirimus, Inc. and consulting at Revolution Medicines, Inc.
His lab develops genetically engineered mouse models and organoid systems for studying cancer progression, with emphasis on metastasis, drug resistance, and epigenetic adaptations. The work has significant implications for improving cancer therapies through context-dependent targeting.
